Neutrisci Receives Additional Order for Japanese Market

VANCOUVER, BC / ACCESSWIRE / May 3, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company")(TSXV:NU)(OTCQB:NRXCF)(FSE:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that Tabletz LLC. has placed an additional order for the TABLETZ product that will be delivered to a specific retailer in Japan.

This small order is in addition to the multi-million dollar order that NeutriSci is in the process of fulfilling for Tabletz's country wide product launch, and consists of several thousand 3-tab sticks, including all 3 flavors - Mint, Lemon, and Berry. NeutriSci plans to ship this order around the end May or beginning of June 2021. While the plan is for TABLETZ to be launched in up to 46,000 locations in Japan, this production request is being provided on a ‘rush' basis for one of the Tabletz LLC's retail partners in order to facilitate a ‘first-to-market' strategy for this retailer.

Glen Rehman, CEO of NeutriSci, commented, "Tabletz has requested that we produce an additional order for one of its retail partners so they can have the product on their store shelves during the first half of June. We are pleased to work with Tabletz LLC, helping them facilitate this request helps to further strengthen our long-term partnership. Once this order has been completed, we will continue to produce the remainder of Tabletz's larger order."

About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for its products offering co-branding as well as private label opportunities and contract manufacturing services. For more information, please visit: www.neutrisci.com.

On Behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320

For investor inquiries, please contact investors@neutrisci.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.

SOURCE: NeutriSci International Inc